

1 ***The Accuracy of the Uganda National Tuberculosis and Leprosy Program algorithm and the World***

2 ***Health Organisation treatment decision algorithms for childhood tuberculosis: A retrospective analysis***

3 Authors: Peter J Kitonsa^{#1,2}, Bernard Kikaire², Peter Wambi¹, Annet Nalutaaya¹, Jascent Nakafeero¹,

4 Gertrude Nanyonga¹, Emma Kiconco¹, Deus Atwiine^{1,3}, Robert Castro⁴, Ernest A Oumo¹, Hellen T Aanyu³,

5 Mary N Mudiope⁵, Ezekiel Mupere², Moorine P Sekadde⁶, Swomitra Mohanty⁷, Adithya Cattamanchi^{1,4,8,9},

6 Eric Wobudeya^{**1,3}, Devan Jaganath^{**1,9,10}

7

8 ¹Uganda Tuberculosis Implementation Research Consortium (U-TIRC), Walimu, Kampala, Uganda.

9 ² Department of Pediatrics and Child Health, College of Health Sciences, Makerere University, Kampala,
10 Uganda.

11 ³ Department of Pediatrics and Child Health, Mulago National Referral Hospital, Kampala, Uganda.

12 ⁴ Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, United States
13 America.

14 ⁵ Infectious Diseases Institute, Kampala, Uganda

15 ⁶ National TB and Leprosy Programme (NTLP), Ministry of Health, Kampala, Uganda

16 ⁷ Departments of Chemical and Metallurgical Engineering, University of Utah, Salt Lake City, United States

17 ⁸ Division of Pulmonary Diseases and Critical Care Medicine, University of California, Irvine, United States

18 ⁹ Center for Tuberculosis, Institute for Global Health Sciences, University of California, San Francisco,
19 United States America

20 ¹⁰ Division of Pediatric Infectious Diseases, University of California, San Francisco, United States America

21

22 ****Co-senior authors; # Corresponding author, kitonsap@gmail.com**

23

24

25

26

27 ABSTRACT

28 Diagnosing childhood pulmonary tuberculosis (TB) is a challenge, and this led the Uganda National
29 Tuberculosis and Leprosy Program (NTLP) to develop a clinical treatment decision algorithm (TDA) for
30 children. However, there is limited data on its accuracy and how it compares to new World Health
31 Organization (WHO) TB TDAs for children. This study aimed to evaluate and compare the accuracy of the
32 2017 Uganda NTLP algorithm with the 2022 WHO TDAs for TB among children in Kampala, Uganda.

33

34 We retrospectively assessed children <15 years old who underwent an evaluation for TB between
35 November 2018 and November 2022. Children were classified as per National Institutes of Health (NIH)
36 consensus definitions. We applied the 2017 Uganda NTLP and 2022 WHO algorithms (A with chest x-ray
37 [CXR], B without CXR) to make a decision to treat for TB or not, and calculated accuracy in reference to
38 Confirmed vs. Unlikely TB, as well as a microbiological and composite reference standard. We compared
39 accuracy of the Uganda NTLP algorithm to the WHO TDAs among children <10 years old.

40

41 A total of 699 children were included in this analysis with 64% (451/699) under 5 years, 53% (373/669)
42 were male, 12% (85/699) were Xpert Ultra positive, 11% (74/669) were HIV positive and 6% had severe
43 acute malnutrition (SAM). The Uganda NTLP algorithm had a sensitivity of 97.9% (95% CI: 96.4-99.4) and
44 specificity of 25.9% (95% CI: 21.2-30.7). If CXR was considered unavailable, sensitivity was 97.9% (95% CI:
45 96.4-99.4) and specificity 28.1% (95% CI: 23.2-33.0). Accuracy remained similar among high-risk children.
46 In comparison, WHO TDAs had similar sensitivity to the Uganda NTLP, but algorithm A was more specific
47 (32.2%, 95% CI: 26.9-37.5) and algorithm B was less specific (15.4%, 95% CI: 11.3-19.5).

48

49 Both the Uganda NTLP and WHO TDAs had high sensitivity but low specificity. The WHO TDAs had better
50 specificity than the NTLP algorithm with CXR, and worse specificity without CXR. Further optimization of
51 the algorithms is needed to improve specificity and reduce over-treatment of TB in children.

52

53 INTRODUCTION

54 Childhood pulmonary tuberculosis (TB) presents a diagnostic challenge due to its non-specific
55 presentation and difficulties in obtaining respiratory specimens because young children (who are most
56 vulnerable) cannot expectorate. Additionally, sputum evaluation by smear and molecular testing is often
57 negative due to the paucibacillary nature of childhood TB.^[1,2] Moreover, children often present at primary
58 care facilities, which may lack the infrastructure for molecular testing or chest X-ray (CXR) to support TB
59 evaluation and timely diagnosis. Consequently, there are large delays in TB treatment, which may explain
60 why globally only 41% of the United Nations (UN) high-level meeting target of 3.5 million children on TB
61 treatment was achieved.^[1]

62 To reduce the delays in TB treatment initiation for children, treatment decision algorithms (TDAs) have
63 been developed to guide providers on empiric treatment based on signs and symptoms. In Uganda, the
64 National TB and Leprosy Program (NTLP) developed an algorithm that has been implemented since
65 2017.^[3] In 2022, the World Health Organization (WHO) conditionally recommended the use of TDAs for
66 childhood TB, and presented an algorithm based on signs and symptoms as well as scores with CXR
67 (Algorithm A) or without CXR (Algorithm B).^[4] However, there are limited data on the accuracy of these
68 algorithms, and their use may result in over- or under-diagnosis of TB among children. Moreover, it is
69 unclear if the new WHO algorithms should be utilized in Uganda or the current Uganda NTLP algorithm
70 continued or updated.

71 To better define the role of these algorithms, we retrospectively analyzed four years of clinical data from
72 children in Kampala, Uganda who underwent a standard TB evaluation and were classified according to
73 National Institutes of Health (NIH) consensus definitions for childhood TB. We utilized this data to
74 determine the accuracy of the Uganda NTL algorithm, and also to compare its accuracy it to the WHO
75 TDAs in same age group, and how accuracy varied based on access to Xpert and/or CXR.

76

77 MATERIALS AND METHODS

78 Study Population

79 De-identified data (accessed, 6th December 2022) from children aged 0 - 14 years who underwent an
80 evaluation for possible pulmonary TB between 28th November 2018 and 30th November 2022 was
81 included for this analysis. The parent study recruited children from 28th November 2018 to 19th September
82 2024, situated at the Mulago National Referral Hospital Pediatric TB clinic within the Mulago National
83 Referral Hospital (MNRH).^[5] The TB clinic recruited children from the MNRH pediatric wards, Mulago
84 assessment center, other clinics and hospitals in and around Kampala (including Kampala Capital City
85 Council (KCCA) clinics/health facilities and Infectious Diseases Institute (IDI) clinics), and referrals from
86 upcountry health facilities. After evaluation, children returned to their referring facilities for further care.
87 MNRH provides approximately 500,000 outpatient visits per year including from specialized clinics.^[5] The
88 hospital's immediate catchment area includes Kampala, Mukono and Wakiso districts with a population
89 of approximately 1.8, 0.9 million and 3.4 million respectively^[6] with the main languages spoken being
90 Luganda and English. The hospital is also a national center of excellence that attends to patients from the
91 entire country.

92 Children were consecutively enrolled and included if they had cough at least 1 week and at least two of
93 the following: unexplained fever >1 week, weight loss (>5% reduction compared to highest recorded

94 weight in prior 3 months), poor appetite, poor weight gain/failure to thrive (weight-for-age or weight-for-
95 height/length z-scores ≤ -3), unexplained lethargy or reduced playfulness >1 week, abnormal chest x-ray or
96 history of TB contact. Children who were already on TB treatment, or history of TB disease in the last year,
97 were excluded. Our analysis was restricted to children who met the Uganda intensified TB case finding
98 (ICF) guide^[3] definition of presumptive TB applied at all entry points: any one of persistent cough ≥ 2 weeks
99 or any duration if HIV positive: persistent fevers ≥ 2 weeks: poor weight gain in the last ≥ 1 month; TB
100 contact, or swellings in the neck, armpit or groin.

101 TB evaluation procedures

102 Participants completed an interview, which included a standardized questionnaire about TB symptoms
103 and signs and the duration of each, along with questions about their sociodemographic information and
104 potential TB risk factors. The clinical evaluation included physical examination, CXR, Tuberculin skin
105 testing (TST), and HIV testing. Respiratory specimen collection included expectorated or induced sputum,
106 gastric aspiration, or nasopharyngeal aspiration, and was sent for Gene Xpert MTB/RIF Ultra testing
107 [Cepheid, Sunnyvale, USA] and solid or liquid mycobacterial culture. Xpert Ultra trace semi-quantitative
108 results were considered positive. Additional details have been previously published.^[7]

109 All individuals had their weight (in kg) and height/length (in meters) taken using a weighing scale and
110 SECA-216 stadiometer (Seca Industries, Hamburg), respectively. All children had a follow up visit
111 regardless of TB diagnosis at 2 months to assess ongoing or resolved signs and symptoms and any
112 response to anti-TB treatment.

113 Classification of TB status by Treatment Decision Algorithms

114 According to the NTL algorithm^[3], if a child < 15 years old meets ICF criteria for presumptive TB, it is
115 recommended to obtain a respiratory specimen for molecular testing with Xpert MTB/RIF Ultra. If MTB
116 detected, they are treated for TB. If MTB is not detected, decision to treat was based on whether they

117 met ≥ 2 of the following criteria if HIV negative OR ≥ 1 criteria if HIV positive; 1. 2 or more TB symptoms
118 (persistent fever ≥ 2 weeks, persistent cough ≥ 2 weeks, poor weight gain ≥ 1 month), 2. positive history of
119 TB contact (bacteriologically confirmed), 3. CXR suggestive of TB, and 4. any physical signs suggestive of
120 TB. Physical signs suggestive of TB included: severe malnutrition, cervical, axilla or groin
121 lymphadenopathy, features of pneumonia not responding to broad spectrum antibiotics.

122 The 2022 WHO TB treatment decision algorithms (TDAs) A and B were developed for children < 10 years
123 old, and so analysis was limited to this age group.^[8] The algorithms both recommend molecular testing
124 for children with presumptive pulmonary TB. If negative or unavailable, a TB score is calculated that
125 assigns points to TB signs and symptoms, with TB treatment decision when the total score ≥ 10 . The
126 algorithms differ in whether CXR is available (A) or is not (B), with corresponding different scores assigned
127 to the TB features.

128 We analyzed TB treatment decisions for four scenarios: (1) when Xpert and CXR is available; (2) when only
129 CXR is available; (3) when only Xpert is available; and (4) when neither Xpert nor CXR is available. The
130 Uganda NTLP algorithm was also evaluated for all the four scenarios, and WHO algorithm A for (1) and
131 (2), and algorithm B for (3) and (4).

132 Reference Standard

133 Children were classified as Confirmed TB (positive Xpert or culture), Unconfirmed TB (negative
134 microbiological testing but consideration of other signs and symptoms of TB and response to TB
135 treatment) or Unlikely TB (not meeting other criteria) using the NIH consensus definitions.^[9] They were
136 unclassifiable if there was insufficient data to determine TB status. Two pediatric TB experts classified
137 each participant independently and blinded to the TDA calculation, with a third reviewer as a tiebreaker
138 if needed. We used the following reference standards:

139 1. **Confirmed TB versus Unlikely TB.** This excludes children with Unconfirmed TB.

140 2. **Composite reference standard (CRS).** Confirmed or Unconfirmed are defined as TB, and Unlikely
141 as not having TB.

142 3. **Microbiologic reference standard (MRS).** Confirmed TB was defined as TB, and Unconfirmed or
143 Unlikely TB as not having TB.

144 Statistical methods

145 Descriptive statistics were computed to describe relevant characteristics, and categorical variables were
146 summarized using frequencies and proportions and all continuous variables were summarized using
147 medians and interquartile range (IQR). Our primary objective was to determine the accuracy of the
148 algorithms. Utilizing each reference standard above, we calculated the sensitivity and specificity of the
149 Uganda NTL algorithm (children <15years) and the WHO TDAs (children <10 years) for the overall and
150 for key subgroups of children <5 years old, with SAM, or living with HIV.

151 We further compared the accuracy of the Uganda NTL algorithm with that of the WHO TDAs, among
152 children <10 years. We compared the sensitivity and specificity of each algorithm using McNemar's test,
153 with significance defined as p-value < 0.05.

154 Stata version 13.0 (Statacorp, College Station, USA) was used for this analysis.^[10]

155 Ethical Considerations

156 The study was approved by the Ethics Review Committee of the Makerere University School of Medicine
157 Research and Ethics Committee as well as the Mulago Hospital Research and Ethics Committee,
158 Kampala, Uganda (IRB number 12884), and the institutional review board at the University of California,
159 San Francisco (UCSF), United States. All children 8 to <15 years provided informed written assent and
160 parental/guardian written consent where as children <8 years, only parental/guardian informed written
161 consent was obtained for all study activities.

162 RESULTS

163 Participant characteristics and TB.

164 Between November 2018 to November 2022, there was a total of 875 children with TB symptoms of whom
165 867 met the intensified TB case finding (ICF) criteria, and of whom 842 were enrolled into the study (Figure
166 1). TB status was unclassifiable for 143 participants and 25 did not consent; and were excluded. We thus
167 analyzed data from a total of 699 children, of whom 98 (14.1%) had Confirmed TB, 361 (51.6%) had
168 Unconfirmed TB, and 240 (34.3%) had Unlikely TB.

169 The participants' median age was 3 years (Interquartile Range, IQR: 1-6), 53% (373/699) were male, 64%
170 (451/699) were aged <5 years, 92% (642/699) were aged <10 years, 57% (399/699) had history of TB
171 contact, and 6% (42/699) had severe acute malnutrition (SAM). There were 74 (11%) children with HIV
172 (CHIV), and 12% (85/699) of children had a positive Xpert result (Table 1).

173 Diagnostic accuracy of the Uganda NTL Algorithm

174 When CXR was available, the overall sensitivity was 97.9% (95% CI: 96.4-99.4) among Confirmed vs.
175 Unlikely TB, 90.7% (95% CI: 88.5-92.9) with the CRS, and 97.9% (95% CI: 96.4-99.4) with MRS. Specificity
176 was 25.9% (95% CI: 21.2-30.7) in reference to Confirmed vs. Unlikely TB and the CRS, and 17.1% (95% CI:
177 14.3-20.0) with the MRS. (Table 2)

178 When CXR was unavailable, the sensitivity remained the same in reference to Confirmed vs. Unlikely TB
179 and the MRS, and reduced modestly with the CRS from 90.7% to 88.4%. In contrast, there were small
180 increases in specificity and ranged from 19.7% to 28.1%. (Table 2)

181

182 Accuracy of the Uganda NTL algorithm by risk group

183 We evaluated the accuracy of the NTL algorithm among children less than 5 years, CHIV, and those with
184 SAM (Table 3). For each reference standard, the sensitivity and specificity remained similar to the overall

185 estimate with overlapping confidence intervals. Similar to the overall estimate, the specificity slightly
186 increased without CXR.

187

188 Accuracy of the WHO algorithms A and B

189 The accuracy of the WHO TDAs (children <10 years) is shown in Table 2. Similar to the NTLT, sensitivity
190 was high but specificity was low across reference standards. However, in contrast, specificity varied
191 depending on availability of CXR, with higher specificity when CXR was available for WHO algorithm A.

192

193 Comparison of the diagnostic accuracy of the 2017 Uganda NTLT algorithm and the 2022 WHO childhood

194 TB diagnosis algorithms

195 Among children <10 years, the accuracy of the Uganda NTLT algorithm and the WHO TDAs varied
196 depending on the availability of Xpert and/or CXR (Table 4). We found that across the scenarios, the
197 sensitivity between the Uganda NTLT and WHO TDAs remained similar, except WHO TDA-B had higher
198 sensitivity compared to Uganda NTLT algorithm when CXR was not available against the CRS only (94.2%
199 vs. 87.5% without CXR or Xpert, difference of -7.0, [95% CI: -10.7, -3.2], $p < 0.01$). Specificity depended
200 on the availability of CXR; if CXR was available, WHO TDA-A was more specific than the Uganda NTLT
201 algorithm regardless of Xpert access. However, if CXR was unavailable, specificity was lower in WHO
202 TDA-B compared to Uganda NTLT algorithm, across reference standards.

203

204 DISCUSSION

205 In this study, we sought to determine the accuracy of the Uganda NTLT algorithm and also compare its
206 accuracy to the WHO TDAs. We found that the Uganda NTLT algorithm had a high sensitivity but low
207 specificity, under both microbiologic and composite reference standards, and the accuracy remained

208 similar (high sensitivity and low specificity) in key risk groups (children < 5 years, CHIV, or SAM). Both the
209 WHO TDA and the Uganda NTLP algorithms had similarly high sensitivity, but specificity was higher for the
210 WHO TDA-A in settings with CXR available, while the Uganda NTLP algorithm had higher specificity in
211 settings without molecular testing and/or CXR. Our findings point to the need for tools to augment the
212 specificity of these algorithms, especially if molecular testing or CXR is not available.

213

214 The high sensitivity of the Uganda NTLP algorithm supports the goal of reducing missed TB cases, and
215 previous work has shown that this algorithm increased TB notification among children (<15 years of age)
216 in two Ugandan districts by 41% over an 18-month period.^[11] However, our study raises concern that a
217 large proportion of children are overtreated for TB. As children in the general population are already
218 screened first for symptoms or risk factors prior to utilizing the Uganda NTLP algorithm, greater specificity
219 is needed. For the CRS, we found a small reduction in sensitivity when children with Unconfirmed TB were
220 included, as expected given this is a heterogenous group and may include children without true TB
221 disease. Our results were in contrast to an individual participant data (IPD) meta-analysis that showed the
222 Uganda NTLP algorithm to have a lower sensitivity of 67% and higher specificity of 39%,^[12] though there
223 was wide heterogeneity across studies, with a range of 33-97% sensitivity and 15-85% specificity.
224 However, across reference standards, the sensitivity remained high and specificity was low, with
225 implications for overtreatment of children. This was also true in subgroup analysis looking at CHIV, SAM,
226 or below 5 years old. It may be appropriate to over-treat these higher risk groups, but further work is
227 needed to understand the potential harms including side effects or missed alternative diagnoses.

228

229 The accuracy of the WHO TDAs was consistent with the IPD meta-analysis that found the pooled
230 sensitivity and specificity at 80% and 30% respectively.^[12] Our higher sensitivity may be explained by the

231 fact that children in our study were first screened using a more sensitive ICF, as similarly seen among
232 adults in Kampala where there was a 6% increase in TB case notifications as a result of ICF
233 implementation.^[13] Comparing the Uganda NTLP algorithm and WHO TDAs, the sensitivity remained high
234 regardless of Xpert, reflecting that these have been developed in particular for empiric treatment when
235 microbiological testing is not available or frequently negative, given paucibacillary disease in children. The
236 Uganda NTLP algorithm's accuracy remained stable with or without CXR, unlike the WHO TDA's specificity
237 that dropped in scenarios where CXR was unavailable. A possible reason for this is how each algorithm is
238 scored. For the Uganda NTLP algorithm, the presence or absence of specific signs or symptoms are equally
239 weighted, and so more children may be diagnosed with TB for example regardless of CXR findings. In
240 contrast, the WHO TDAs assign points that differentially weight signs and symptoms, including specific
241 CXR findings. Moreover, the assigned points are different whether CXR is present or not, and the internal
242 validation data showed that the model with CXR had greater specificity.^[12] From an implementation
243 perspective, the WHO TDAs and algorithms with a similar approach may be most valuable in settings with
244 both Xpert and CXR available, but those are facilities where providers may have more experience with
245 diagnosing TB. Although the Uganda NTLP algorithm had lower specificity, this was higher than WHO
246 algorithm B and it remained stable with or without CXR; it therefore may be preferable in lower-level
247 health facilities which may not have molecular or radiological testing facilities. Policy makers will need to
248 balance the benefits of detecting more cases with the costs of over-treatment and expanding access to
249 molecular testing with CXR to improve specificity.

250

251 Our study adds much needed data on the accuracy of the Uganda NTLP algorithm and its comparison to
252 the WHO TDAs. We further present the accuracy results based on availability of CXR and Xpert to guide
253 how these algorithms may perform in different types of settings. However, our study had limitations. The
254 CRS is challenging because Unconfirmed TB can be greatly influenced by provider treatment initiation,

255 which in turn may have been informed by the NTL algorithm given it is implemented at the facility.
256 Therefore, we will have high incorporation bias as the CRS includes both Xpert, CXR and clinical decision
257 to treat. Another limitation is that we looked at urban children with presumptive TB and therefore our
258 results may not generalize to rural or migratory populations. Additionally, the assessment was done by
259 study staff focused on the evaluation of TB and all children provided respiratory samples, which could
260 reduce generalizability. Also, our analysis was restricted to only children who fulfilled the ICF criteria;
261 however, only eight children were excluded as a result of this requirement.

262 In summary, our study shows that if implemented in its current form, the Uganda NTL algorithm and
263 WHO TDAs have high sensitivity to capture most cases of childhood TB, but may result in overdiagnosis
264 and overtreatment of children without TB. Our study further highlights a potential limitation of
265 implementing the WHO TDAs over the Uganda NTL algorithm in primary care clinics without access to
266 CXR or molecular testing. As new TB diagnostics emerge, it will be important to integrate them into TDAs
267 to assess incremental changes in accuracy.

268

269 ACKNOWLEDGMENT


270 We thank the patients, families, and staff at Mulago National Referral Hospital, Kampala Capital City
271 Authority Clinics, and Infectious Diseases Institute (IDI) clinics. The study was supported by the National
272 Institutes of Health (R01HL139717 and U01AI152087 to AC, and R01HL169449 and K23HL153581 to DJ).
273 The content is solely the responsibility of the authors and does not necessarily represent the official views
274 of the National Institutes of Health.

275 REFERENCES

- 276 1. Organisation, W.H., *Global tuberculosis report 2021*, WHO, Editor. 2021: Geneva.
- 277 2. Wobudeya, E., et al., *Trend and outcome of notified children with tuberculosis during 2011-2015*
- 278 *in Kampala, Uganda*. BMC Public Health, 2017. **17**(1): p. 963.
- 279 3. Ministry Of Health, U., *Manual for control and Management of Tuberculosis and Leprosy*, MOH,
- 280 Editor. 2017.
- 281 4. Organisation, W.H., *WHO consolidated guidelines on tuberculosis Module 5: Management of*
- 282 *tuberculosis in children and adolescents*.
- 283 <https://www.who.int/publications/i/item/9789240046764>, ed. W. Team. March, 2022.
- 284 5. Ministry of Health, U. *Mulago National Referral Hospital*. Available from:
- 285 <https://www.health.go.ug/sermon/mulago-national-referral-hospital/>.
- 286 6. Review, W.P., *Uganda Demographics*. 2021,
- 287 <https://worldpopulationreview.com/countries/uganda-population>.
- 288 7. Jaganath, D., et al., *A Prospective Evaluation of Xpert MTB/RIF Ultra for Childhood Pulmonary*
- 289 *Tuberculosis in Uganda*. J Pediatric Infect Dis Soc, 2021. **10**(5): p. 586-592.
- 290 8. Organization, W.H., *WHO operational handbook on tuberculosis Module 5: Management of*
- 291 *tuberculosis in children and adolescents*.
- 292 <https://www.who.int/publications/i/item/9789240046832>, ed. P. 73-74. 2021: World Health
- 293 Organization.
- 294 9. Graham, S.M., et al., *Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in*
- 295 *Children: An Update*. Clin Infect Dis, 2015. **61**Suppl 3(Suppl 3): p. S179-87.
- 296 10. StataCorp, *StataCorp*. 2013. *Stata Statistical Software: Release 13*. College Station, TX: StataCorp
- 297 LP. 2013.
- 298 11. Zawedde-Muyanja, S., et al., *Decentralisation of child tuberculosis services increases case finding*
- 299 *and uptake of preventive therapy in Uganda*. Int J Tuberc Lung Dis, 2018. **22**(11): p. 1314-1321.
- 300 12. Gunasekera, K.S., et al., *Development of treatment-decision algorithms for children evaluated for*
- 301 *pulmonary tuberculosis: an individual participant data meta-analysis*. Lancet Child Adolesc
- 302 Health, 2023. **7**(5): p. 336-346.
- 303 13. Hermans, S.M., et al., *Integration of HIV and TB Services Results in Improved TB Treatment*
- 304 *Outcomes and Earlier Prioritized ART Initiation in a Large Urban HIV Clinic in Uganda*. JAIDS
- 305 Journal of Acquired Immune Deficiency Syndromes, 2012. **60**(2): p. e29-e35.

306

Figure 1: Study cohort flowchart



medRxiv preprint doi: <https://doi.org/10.1101/2024.11.20.24317633>; this version posted November 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 1: Characteristics of enrolled children with presumptive pulmonary tuberculosis in Kampala, Uganda (n=699)

Characteristic	n (%)
Age Category	
< 1 year	80 (11.4%)
1 - < 5 years	371 (53.1%)
5 - < 10 years	191 (27.3%)
10 - < 15 years	57 (8.2%)
Male sex	373 (53.4%)
Has fever¹	560 (80.5%)
Has lymphadenopathy¹	332 (47.6%)
Has weight loss	271 (38.8%)
Failed to gain weight¹	584 (84.0%)
Has TB contact	399 (57.1%)
HIV Positive¹	74 (11.1%)
Severe acute malnutrition	42 (6.0%)
Chest X-ray interpretation¹	
Normal	387 (61.5%)
Abnormal - Equivocal	129 (20.5%)
Abnormal - Likely TB	113 (18.0%)
Xpert MTB/RIF Ultra Positive	85 (12.2%)

1. 3 missing fever, 1 missing lymphadenopathy, 4 missing Failure to gain weight, 30 missing HIV status, and 70 missing chest-xray.

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.20.24317633>; this version posted November 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 2: Diagnostic accuracy of the 2017 Uganda national childhood TB diagnosis algorithm (NTLP) and the 2022 WHO TB diagnosis algorithms A & B under three reference standards with or without chest x-ray (CXR). Xpert results were incorporated into the TDA classification

Confirmed TB versus Unlikely TB		
Algorithm^{1,2}	Sensitivity (95% CI)	Specificity (95% CI)
With CXR		
Uganda NTLP	97.9 (96.4, 99.4)	25.9 (21.2, 30.7)
WHO Algorithm A	96.3 (94.2, 98.5)	32.2 (26.9, 37.5)
Without CXR		
Uganda NTLP	97.9 (96.4, 99.4)	28.1 (23.2, 33.0)
WHO Algorithm B	97.5 (95.8, 99.3)	15.4 (11.3, 19.5)
Composite Reference Standard (CRS)		
Algorithm	Sensitivity (95% CI)	Specificity (95% CI)
With CXR		
Uganda NTLP	90.7 (88.5, 92.9)	25.9 (22.6, 29.2)
WHO Algorithm A	89.3 (86.8, 91.7)	32.2 (28.5, 35.9)
Without CXR		
Uganda NTLP	88.4 (86.0, 90.9)	28.1 (24.7, 31.5)
WHO Algorithm B	94.2 (92.4, 96.1)	15.4 (12.5, 18.2)
Microbiologic Reference Standard (MRS)		
Algorithm	Sensitivity (95% CI)	Specificity (95% CI)
With CXR		
Uganda NTLP	97.9 (96.8, 99.0)	17.1 (14.3, 20.0)
WHO Algorithm A	96.3 (94.9, 97.8)	20.4 (17.3, 23.5)
Without CXR		
Uganda NTLP	97.9 (96.8, 99.0)	19.7 (16.7, 22.8)
WHO Algorithm B	97.5 (96.3, 98.8)	10.1 (7.7, 12.4)

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.20.24317633>; this version posted November 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).

CXR- chest x-ray

WHO Algorithm A-settings with chest X-ray.

WHO Algorithm B-settings without chest X-ray

1. Algorithms were applied to the age group they were indicated for: the NTLP for children <15 years, and <10 years for the WHO TDAs

2. Xpert Ultra results included in the algorithms

Table 3: Accuracy of the 2017 Uganda national childhood TB diagnosis algorithm (NTLP) by risk group (Age < 5 years, SAM, and HIV) under three reference standards with or without chest x-ray (CXR) for children <15 years old.

Confirmed TB versus Unlikely TB		
Group	Sensitivity (95% CI)	Specificity (95% CI)
Age < 5 years		
<i>With CXR</i>	98.3 (96.5, 100.1)	29.4 (23.0, 35.7)
<i>Without CXR</i>	98.3 (96.5, 100.1)	32.3 (25.8, 38.8)
SAM		
<i>With CXR</i>	97.6 (95.9, 99.3)	25.7 (20.7, 30.7)
<i>Without CXR</i>	97.6 (95.9, 99.3)	28.1 (22.9, 33.2)
HIV		
<i>With CXR</i>	97.5 (95.7, 99.3)	25.7 (20.6, 30.7)
<i>Without CXR</i>	97.5 (95.7, 99.3)	28.1 (22.9, 33.2)
Composite Reference Standard (CRS)		
Group	Sensitivity (95% CI)	Specificity (95% CI)
Age < 5 years		
<i>With CXR</i>	89.9 (87.0, 92.7)	29.4 (25.1, 33.7)
<i>Without CXR</i>	88.2 (85.1, 91.2)	32.3 (27.9, 36.7)
SAM		
<i>With CXR</i>	90.6 (88.3, 92.9)	25.7 (22.2, 29.1)
<i>Without CXR</i>	88.9 (86.5, 91.4)	28.1 (24.5, 31.6)
HIV		
<i>With CXR</i>	90.5 (88.2, 92.8)	25.7 (22.2, 29.1)
<i>Without CXR</i>	88.8 (86.3, 91.3)	28.1 (24.5, 31.6)
Microbiologic Reference Standard (MRS)		
Group	Sensitivity (95% CI)	Specificity (95% CI)
Age < 5 years		
<i>With CXR</i>	98.3 (97.1, 99.5)	18.5 (14.8, 22.2)
<i>Without CXR</i>	98.3 (97.1, 99.5)	20.9 (17.1, 24.8)
SAM		
<i>With CXR</i>	97.9 (96.8, 99.0)	19.7 (16.7, 22.8)
<i>Without CXR</i>	97.6 (96.4, 98.8)	19.1 (16.0, 22.2)
HIV		
<i>With CXR</i>	97.5 (96.2, 98.7)	16.8 (13.9, 19.8)
<i>Without CXR</i>	97.5 (96.2, 98.7)	19.1 (16.0, 22.2)

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.20.24317633>; this version posted November 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 4: Comparison of 2017 Uganda national childhood TB diagnosis algorithm (NTLP) against 2022 WHO childhood TB treatment decision algorithms among children <10 years old with and without Xpert testing or Chest X-ray imaging

Scenario	NTLP		WHO Algorithm A/B ¹		Difference in Sensitivity (NTLP vs. WHO) % (95% CI), p-value	Difference in Specificity (NTLP vs. WHO) % (95% CI), p-value
	Sensitivity %, (95%CI)	Specificity %, (95%CI)	Sensitivity %, (95%CI)	Specificity %, (95%CI)		
Confirmed TB Vs. Unlikely TB						
Xpert + CXR	97.6 (95.9, 99.3)	25.7(20.7, 30.7)	96.3 (94.2, 98.5)	32.2 (26.9, 37.5)	1.3 (-2.3, 4.5), 1.00	-6.8 (-11.9, -1.7), 0.01
Xpert	97.6 (95.9, 99.3)	28.1 (22.9, 33.2)	97.5 (95.8, 99.3)	15.4 (11.3, 19.5)	0 (-1.2, 1.2), 1.00	12.1 (5.3, 19.0), <0.01
CXR	93.7 (90.9, 96.5)	25.7 (20.6, 30.7)	96.3 (94.2, 98.5)	32.2 (26.9, 37.5)	-2.5 (-3.7, 8.8), 0.62	-6.8 (-11.9, -1.7), <0.01
None	91.2 (88.0, 94.5)	28.1 (22.9, 33.2)	97.5 (95.8, 99.3)	15.4 (11.3, 19.5)	-6.4 (-0.3, 13.1), 0.06	12.1 (5.3, 19.0), <0.01
Composite reference standard (CRS)						
Xpert + CXR	90.6 (88.3, 92.9)	25.7 (22.2, 29.1)	89.3 (86.8, 91.7)	32.2 (28.5, 35.9)	1.0 (-1.9, 4.0), 0.58	-6.8 (-11.9, -1.7), <0.01
Xpert	88.9 (86.5, 91.4)	28.1 (24.5, 31.6)	94.2 (92.4, 96.1)	15.4 (12.5, 18.2)	-5.6 (2.1, 9.2), <0.01	12.1 (5.3, 19.0), <0.01
CXR	89.8 (87.4, 92.2)	25.7 (22.2, 29.1)	89.3 (86.8, 91.7)	32.2 (28.5, 35.9)	0 (-2.9, 3.4), 1.00	-6.8 (-11.9, -1.7), <0.01
None	87.5 (84.9, 90.2)	28.1 (24.5, 31.6)	94.2 (92.4, 96.1)	15.4 (12.5, 18.2)	-7.0 (-10.7, -3.2), <0.01	12.1 (5.3, 19.0), <0.01
Microbiologic reference standard (MRS)						
Xpert + CXR	97.6 (96.4, 98.8)	16.8 (13.9, 19.8)	96.3 (94.9, 97.8)	20.4 (17.2, 23.5)	1.2 (-2.3, 4.7), 1.00	-3.3 (-0.3, 6.2), 0.02
Xpert	97.6 (96.4, 98.8)	19.1 (16.0, 22.2)	97.5 (96.3, 98.8)	10.1 (7.7, 12.4)	0 (-1.2, 1.2), 1.00	9.1 (5.4, 12.9), <0.01
CXR	93.7 (91.8, 95.6)	16.8 (13.9, 19.8)	96.3 (94.9, 97.8)	20.4 (17.2, 23.5)	-2.5 (-3.7, 8.8), 0.62	-3.3 (-0.3, 6.2), 0.02
None	91.2 (89.0, 93.4)	19.1 (16.0, 22.2)	97.5 (96.3, 98.8)	10.1 (7.7, 12.4)	-6.4 (-0.3, 13.1), 0.06	9.1 (5.4, 12.9), <0.01

Xpert: Xpert MTB/RIF Ultra; CXR: Chest x-ray

1. Algorithm A used in scenarios with CXR, Algorithm B in scenarios without CXR